ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas

Neuroendocrinology

Volumn 95, Issue 2, 2012, Pages 135-156

  Pape, Ulrich Frank ^a   Perren, Aurel ^b   Niederle, Bruno ^c   Gross, David ^d   Gress, Thomas ^e   Costa, Frederico ^f   Arnold, Rudolf ^e   Denecke, Timm ^a   Plöckinger, Ursula ^a   Salazar, Ramon ^g   Grossman, Ashley ^h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f HOSPITAL SÍRIO LIBANÊS   (Brazil)

^g CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

18 FLUORO DIHYDROXYPHENYLALANINE; 5 HYDROXYTRYPTOPHAN; DOPA; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GALLIUM 68; INDIUM 111; TECHNETIUM 99M; UNCLASSIFIED DRUG;

11 CARBON 5 HYDROXYTRYPTOPHANE; ABDOMINAL SCINTISCANNING; ADENOCARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER PROGNOSIS; CARCINOID SYNDROME; CHOLECYSTECTOMY; CLINICAL FEATURE; CONSENSUS; FOLLOW UP; GOBLET CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; ILEUM CANCER; JEJUNO ILEUM CARCINOMA; LABORATORY TEST; NEUROENDOCRINE TUMOR; PALLIATIVE THERAPY; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TRANSTHORACIC ECHOCARDIOGRAPHY; TUMOR LOCALIZATION; TUMOR VOLUME;

APPENDICEAL NEOPLASMS; HUMANS; ILEUM; INTESTINAL NEOPLASMS; JEJUNUM; NEUROENDOCRINE TUMORS;

EID: 84857818285     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000335629     Document Type: Review

References (177)

1. Eriksson B, Klöppel G, Krenning E, et al: Consensus guidelines for the management of patients with digestive neuroendocrine tumours: Well-differentiated jejunal-ileal tumour/carcinoma. Neuroendocrinology 2008; 87: 8-19. (Pubitemid 350308290)
2. Plöckinger U, Couvelard A, Falconi M, et al: Consensus guidelines for the management of patients with digestive neuroendocrine tumours: Well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology 2008; 87: 20-30. (Pubitemid 350308291)
3. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al: ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine tumors of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95:157-176.
4. Ahlman H, Nilsson O, McNicol AM, et al: Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology. 2008; 87: 40-46. (Pubitemid 350308293)
5. Oberndorfer S: Karzinoide Tumoren des Dünndarms. Frankf Z Pathol 1907; 1: 426-423.
6. Ellis L, Shale MJ, Coeman MP: Carcinoid tumors of the gastrointestinal tract: Trends in incidence in England since 1971. Am J Gastroenterol 2010; 105: 2563-2569.
7. Ito T, Sasano H, Tanaka M, et al: Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010; 45: 234-243.
8. Yao JC, Hassan M, Phan A, et al: One hundred years after 'carcinoid': Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
9. Hauso O, Gustafsson BI, Kidd M, et al: Neuroendocrine tumor epidemiology: Contrasting Norway and North America. Cancer 2008; 113: 2655-2664.
10. Landerholm K, Falkmer S, Järhult J: Epidemiology of small bowel carcinoids in a defined population. World J Surg 2010; 34: 1500-1505.
11. Niederle MB, Hackl M, Kaserer K, et al: Gastroenteropancreatic neuroendocrine tumours: The current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: An analysis based on prospectively collected parameters. Endocr Relat Cancer 2010; 17: 909-918.
12. Pape UF, Berndt U, Müller-Nordhorn J, et al: Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008; 15: 1083-1097.
13. García-Carbonero R, Capdevila J, Crespo-Herrero G, et al: Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010; 21: 1794-1803.
14. Lepage C, Bouvier AM, Manfredi S, et al: Incidence and management of primary malignant small bowel cancers: A well-defined French population study. Am J Gastroenterol 2006; 101: 2826-2832. (Pubitemid 44902657)
15. Ploeckinger U, Kloeppel G, Wiedenmann B, et al: The German NET registry: An audit on the diagnosis and therapy of neuroendocrine tumours. Neuroendocrinology 2009; 90: 349-363.
16. Bergestuen DS, Aabakken L, Holm K, et al: Small intestinal neuroendocrine tumors: Prognostic factors and survival. Scand J Gastroenterol 2009; 44: 1084-1091.
17. Berge T, Linell F: Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand 1976; 84: 322-330.
18. Klimstra DS, Arnold R, Capella C, et al: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours of the Digestive System. Lyon, IARC, 2010.
19. Jann H, Roll S, Couvelard A, et al: Neuroendocrine tumors of midgut and hindgut origin: Tumor-node-metastasis classification determines clinical outcome. Cancer 2011; 117: 3332-3341.
20. Boudreaux JP, Klimstra DS, Hassan MM, et al: The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: Well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas 2010; 39: 753-766.
21. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG: Epidemiology and survival in patients with carcinoid disease in the Netherlands. An epidemiological study with 2,391 patients. Ann Oncol 2001; 12: 1295-1300. (Pubitemid 32994760)
22. Perez EA, Koniaris LG, Snell SE, et al: 7,201 carcinoids: Increasing incidence overall and disproportionate mortality in the elderly. World J Surg 2007: 1022-1030. (Pubitemid 46716758)
23. Strosberg J, Gardner N, Kvols L: Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 2009; 89: 471-476.
24. Helland SK, Prosch AM, Viste A: Carcinoid tumours in the gastrointestinal tract -a population-based study from western Norway. Scand J Surg 2006; 95: 158-161. (Pubitemid 44476532)
25. Ahmed A, Turner G, King B, et al: Midgut neuroendocrine tumours with liver metastases: Results of the UKINETS study. Endocr Relat Cancer 2009; 16: 885-894.
26. Pape UF, Böhmig M, Berndt U, et al: Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center. Ann NY Acad Sci 2004; 1014: 222-233. (Pubitemid 38594810)
27. Niederle MB, Niederle B: Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: Current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation. Oncologist 2011; 16: 602-613.
28. Druce MR, Bharwani N, Akker SA, et al: Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine ('carcinoid') tumours of the small bowel. QJM 2010; 103: 177-185.
29. Castillo JG, Filsoufi F, Adams DH, et al: Management of patients undergoing multivalvular surgery for carcinoid heart disease: The role of the anaesthetist. Br J Anaesth 2008; 101: 618-626.
30. Ricke J, Klose KJ, Mignon M, et al: Standardisation of imaging in neuroendocrine tumours: Results of a European delphi process. Eur J Radiol 2001; 37: 8-17. (Pubitemid 32215440)
31. Kaltsas G, Rockall A, Papadogias D, et al: Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004; 151: 15-27. (Pubitemid 39117361)
32. Bader TR, Semelka RC, Chiu VC, et al: MRI of carcinoid tumors: Spectrum of appearances in the gastrointestinal tract and liver. J Magn Reson Imaging 2001; 14: 261-269. (Pubitemid 32801060)
33. Masselli G, Polettini E, Casciani E, et al: Small-bowel neoplasms: Prospective evaluation of MR enteroclysis. Radiology 2009; 251: 743-750.
34. Kamaoui I, De-Luca V, Ficarelli S, et al: Value of CT enteroclysis in suspected smallbowel carcinoid tumors. AJR Am J Roentgenol 2010; 194: 629-633.
35. Doerffel Y, Wermke W: Neuroendocrine tumors: Characterization with contrast-enhanced ultrasonography. Ultraschall Med 2008; 29: 506-514.
36. Van Tuyl SAC, van Noorden JT, Timmer J, et al: Detection of small-bowel neuroendocrine tumors by video-capsule endoscopy. Gastrointest Endosc 2006; 64: 66-72.
37. Johanssen S, Boivin M, Lochs H, et al: The yield of wireless capsule endoscopy in the detection of neuroendocrine tumors in comparison with CT enteroclysis. Gastrointest Endosc 2006; 63: 660-665.
38. Bailey AA, Debinski HS, Appleyard MN, et al: Diagnosis and outcome of small bowel tumors found by capsule endoscopy: A threecenter Australian experience. Am J Gastroenterol 2006; 101: 2237-2243. (Pubitemid 44477549)
39. Belluti M, Fry LC, Schmitt J, et al: Detection of neuroendocrine tumours of the small bowel by double balloon enteroscopy. Dig Dis Sci 2009; 54: 1050-1058.
40. Ezziddin S, Logvinski T, Yong-Hing C, et al: Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2006; 47: 223-233. (Pubitemid 46780886)
41. Orlefors H, Sundin A, Garske U, et al: Wholebody 11 C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005; 90: 3392-3400. (Pubitemid 41014303)
42. Gabriel M, Decristofori C, Kendler D, et al: 68 Ga-DOTA-Tyr 3 -octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518. (Pubitemid 47571404)
43. Buchmann I, Henze M, Engelbrecht S, et al: Comparison of 68 Ga-DOTATOC PET and 111 In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007: 1617-1626. (Pubitemid 47476920)
44. Ruf J, Steffen I, Mehl S, et al: Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECT. Nucl Med Commun 2007; 28: 782-788. (Pubitemid 47345710)
45. Ambrosini V, Tomassetti P, Castellucci P, et al: Comparison between 68 Ga-DOTA-NOC and 18 F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35: 1431-1438.
46. Koopmans KP, Neels OC, Kema IP, et al: Improved staging of patients with carcinoid and islet cell tumours with 18 F-dihydroxyphenyl-alanine and 11 C-5-hydroxytryptophan positron emission tomography. J Clin Oncol 2008; 26: 1489-1495.
47. Haug A, Auernhammer CJ, Wängler B, et al: Intraindividual comparison of 68 Ga-DOTATATE and 18 F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009; 36: 765-770.
48. Montravers F, Kerrou K, Nataf V, et al: Impact of fluorodihydroxyphenylalanine-18 F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab 2009; 94: 1295-1301.
49. Ruf J, Heuck F, Schiefer J, et al: Impact of multiphase 68 Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumours. Neuroendocrinology 2010; 91: 101-109.
50. Prasad V, Baum RP: Biodistribution of the 68 Ga-labeled somatostatin analogue DOTANOC in patients with neuroendocrine tumors: Characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging 2010; 54: 61-67.
51. Prasad V, Ambrosini V, Hommann M, et al: Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68 Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 2010; 37: 67-77.
52. Ruf J, Schiefer J, Furth C, et al: 68 Ga-DOTATOC PET/CT of neuroendocrine tumors: Spotlight on the CT phases of a triple-phase protocol. J Nucl Med 2011; 52: 697-704.
53. Koopmans KP, de Vries EGE, Kema IP, et al: Staging of carcinoid tumours with 18 F-DOPA PET: A prospective, diagnostic accuracy study. Lancet Oncol 2006; 7: 728-734. (Pubitemid 44283659)
54. Orlefors H, Sundin A, Garske U, et al: Whole-body 11 C-5- hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005; 90: 3392-3400. (Pubitemid 41014303)
55. Meijer WG, van der Veer E, Jager PL, et al: Bone metastases in carcinoid tumors: Clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 2003; 44: 184-191.
56. Ardill JE, Erikkson B: The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer 2003; 10: 459-462. (Pubitemid 38094882)
57. Feldman JM, O'Dorisio TM: Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 1986; 81: 41-48.
58. Eriksson B, Oberg K: Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors. Acta Oncol 1991; 30: 477-483.
59. Arnold R, Wilke A, Rinke A, et al: Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008; 6: 820-827.
60. Korse CM, Bonfrer JMG, Aaronson NK, et al: Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumours. Neuroendocrinology 2009; 89: 296-301.
61. Zatelli MC, Torta M, Leon A, et al: Chromogranin A as a marker of neuroendocrine neoplasia: An Italian multicenter study. Endocr Relat Cancer 2007; 14: 473-482. (Pubitemid 47242645)
62. Stridsberg M, Eriksson B, Oberg K, et al: A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003; 177: 337-341. (Pubitemid 36656407)
63. Peracchi M, Gebbia C, Basilisco G, et al: Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 2005; 152: 443-448. (Pubitemid 40439498)
64. Spadaro A, Ajello A, Morace C, et al: Serum chromogranin-A in hepatocellular carcinoma: Diagnostic utility and limits. World J Gastroenterol 2005; 11: 1987-1990. (Pubitemid 40520997)
65. Giusti M, Sidoti M, Augeri C, et al: Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004; 150: 299-303. (Pubitemid 38443779)
66. Massironi S, Fraquelli M, Paggi S, et al: Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Dig Liver Dis. 2009; 41: 31-35.
67. Welin S, Stridsberg M, Cunningham J, et al: Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumours. Neuroendocrinology 2009; 89: 302-307.
68. Meijer WG, Kema IP, Volmer M, et al: Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 2000; 46: 1588-1596.
69. Kema IP, Meijer WG, Meiborg G, et al: Profiling of tryptophan-related plasma indoles in patients with carcinoid tumors by automated, on-line, solid-phase extraction and HPLC with fluorescence detection. Clin Chem 2001; 47: 1811-1820. (Pubitemid 32881194)
70. O'Toole D, Grossman A, Gross D, et al: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Biochemical markers. Neuroendocrinology 2009; 90: 194-202.
71. Hamilton SR AL: Tumours of the Digestive System. Pathology and Genetics. WHO Classification of Tumours. Lyon, ARC Press, 2000.
72. Klimstra DS, Arnold R, Capella C, et al: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours of the Digestive System. Lyon, IARC, 2010.
73. Sobin LH, Gospodarowicz MK, Wittekind C (eds): TNM Classification of Malignant Tumours. Chichester, Wiley & Blackwell, 2009.
74. Rindi G, Klöppel G, Couvelard A, et al: TNM staging of midgut and hindgut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch 2007; 451: 757-762. (Pubitemid 47497934)
75. Welin S, Sorbye H, Sebjornsen S, et al: Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011 (E-pub ahead of print).
76. Volante M, Brizzi MP, Faggiano A, et al: Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumours: A proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007; 20: 1172-1182. (Pubitemid 47609066)
77. Srirajaskanthan R, Watkins J, Marelli L, et al: Expression of somatostatin and dopamine-2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology 2009; 89: 308-314.
78. Miederer M, Seidl S, Buck A, et al: Correlation of immunohistopathological expression of somatostatin receptor-2 with standardised uptake values in 68 Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009; 36: 48-52.
79. Schmitt AM, Riniker F, Anlauf M, et al: Islet-1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol 2008; 32: 420-425. (Pubitemid 351398934)
80. Grabowski P, Schrader J, Wagner J, et al: Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 2008; 14: 7378-7384.
81. Besig S, Voland P, Baur DM, et al: Vascular endothelial growth factors, angiogenesis, and survival in human ileal enterochromaffin cell carcinoids. Neuroendocrinology 2009; 90: 402-415.
82. Voland P, Besig S, Rad R, et al: Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival. Neuroendocrinology 2009; 89: 66-78.
83. Hemminki K, Li X: Familial carcinoid tumors and subsequent cancers: A nationwide epidemiologic study from Sweden. Int J Cancer 2001; 94: 444-448. (Pubitemid 32906079)
84. Hassan MM, Phan A, Li D, et al: Family history of cancer and associated risk of developing neuroendocrine tumors: A case-control study. Cancer Epidemiol Biomarkers Prev 2008; 17: 959-965. (Pubitemid 351536429)
85. Järhult J, Landerholm K, Falkmer S, et al: First report on metastasizing small bowel carcinoids in first-degree relatives in three generations. Neuroendocrinology 2010; 91: 318-323.
86. Tönnies H, Toliat MR, Ramel C, et al: Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation Gut 2001; 48: 536-541. (Pubitemid 32234799)
87. Stancu M, Wu TT, Wallace C, et al: Genetic alterations in goblet cell carcinoids of the vermiform appendix and comparison with gastrointestinal carcinoid tumors. Mod Pathol 2003; 16: 1189-1198. (Pubitemid 38018599)
88. Akerstrom G, Makridis C, Johansson H: Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 1991; 30: 547-553.
89. Rothmund M, Kisker O: Surgical treatment of carcinoid tumors of the small bowel, appendix, colon and rectum. Digestion 1994; 55(suppl 3):86-91.
90. Ahlman H, Wangberg B, Jansson S, et al: Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion 2000; 62(suppl 1):59-68. (Pubitemid 30665941)
91. Makridis C, Oberg K, Juhlin C, et al: Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990; 14: 377-384.
92. Norton JA: Surgical management of carcinoid tumors: Role of debulking and surgery for patients with advanced disease. Digestion 1994; 55(suppl 3):98-103.
93. Goede AC, Winslet MC: Surgery for carcinoid tumours of the lower gastrointestinal tract. Colorectal Dis 2003; 5: 123-128. (Pubitemid 36442832)
94. Sutton R, Doran HE, Williams EMI, et al: Surgery for midgut carcinoid. Endocr Relat Cancer 2003; 10: 469-481. (Pubitemid 38094884)
95. Han SL, Cheng J, Zhou HZ, et al: Surgically treated primary malignant tumor of small bowel: A clinical analysis. World J Gastroenterol 2010; 16: 1527-1532.
96. Hellman P, Lundström T, Ohrvall, et al: Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 2002; 26: 991-997. (Pubitemid 36920298)
97. Eriksson J, Stalberg P, Nilsson A, et al: Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 2008; 32: 930-938.
98. Toumpanakis C, Garland J, Marelli L, et al: Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment Pharmacol Ther 2009; 30: 733-740.
99. Norlen O, Hessman O, Stalberg P, et al: Prophylactic cholecystectomy in midgut carcinoid patients. World Surg 2010; 34: 1361-1367.
100. Schindl M, Kaczirek K, Passler C, et al: Treatment of small intestinal neuroendocrine tumors: Is an extended multimodal approach justified? World J Surg 2002; 26: 976-984. (Pubitemid 36920296)
101. Givi B, Pommier SEJ, Thompson AK, et al: Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery 2006; 140: 891-898. (Pubitemid 44937381)
102. Steinmüller T, Kianmanesh R, Falconi M, et al: Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumours: Foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008; 87: 47-62. (Pubitemid 350308294)
103. Zuetenhorst JM, Bonfrer JM, Korse CM, et al: Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor- and fibroblast growth factor. Cancer 2003; 97: 1609-1615. (Pubitemid 36350703)
104. Norheim I, Oberg K, Theodorsson-Norheim E, et al: Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987; 206: 115-125 (Pubitemid 17104952)
105. Møller JE, Connolly HM, Rubin J, et al: Factors associated with progression of carcinoid heart disease. N Engl J Med 2003; 348: 1005-1015. (Pubitemid 36302245)
106. Møller JE, Pellikka PA, Bernheim AM, et al: Prognosis of carcinoid heart disease: Analysis of 200 cases over two decades. Circulation 2005 22; 112: 3320-3327. (Pubitemid 43739378)
107. Bhattacharyya S, Davar J, Dreyfus G, et al: Carcinoid heart disease. Circulation 2007; 116; 2860-2865. (Pubitemid 350301147)
108. Mansencal N, Mitry E, Bachet JB, et al: Echocardiographic follow-up of treated patients with carcinoid syndrome. Am J Cardiol 2010; 105: 1588-1591.
109. Castillo JG, Filsoufi F, Rahmanian PB, et al: Early and late results of valvular surgery for carcinoid heart disease. J Am Coll Cardiol 2008; 51: 1507-1509. (Pubitemid 351471785)
110. Bhattacharyya S, Raja SG, Toumpanakis C, et al: Outcomes, risks and complications of cardiac surgery for carcinoid heart disease. Eur J Cardiothorac Surg 2011; 40: 168-172.
111. Jacobsen MB, Nitter-Hauge S, Bryde PE, Hanssen LE: Cardiac manifestations in mid-gut carcinoid disease. Eur Heart J 1995; 16: 263-268.
112. Druce M, Rockall A, Grossman AB: Fibrosis and carcinoid syndrome: From causation to future therapy. Nat Rev Endocrinol 2009; 5: 276-283.
113. Sandmann H, Pakkal M, Steeds R: Cardiovascular magnetic resonance imaging in the assessment of carcinoid heart disease. Clin Radiol 2009; 64: 761-766.
114. Mansencal N, McKenna WJ, Mitry E, et al: Comparison of prognostic value of tissue Doppler imaging in carcinoid heart disease versus the value in patients with the carcinoid syndrome but without carcinoid heart disease. Am J Cardiol 2010; 105: 527-531.
115. Bhattacharyya S, ToumpanakisC, Chilkunda D, et al: Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol 2011; 107: 1221-1226.
116. Zuetenhorst JM, Korse CM, Bonfrer JM, et al: Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer 2004; 90: 2073-2079. (Pubitemid 38869708)
117. Bernheim AM, Connolly HM, Rubin J, et al: Role of hepatic resection for patients with carcinoid heart disease. Mayo Clin Proc 2008; 83: 143-150. (Pubitemid 351303098)
118. Mansencal N, Mitry E, Forissier JF, et al: Assessment of patent foramen ovale in carcinoid heart disease. Am Heart J 2006; 151: 1129.e1-6.
119. Mansencal N, Mitry E, Pillière R, et al: Prevalence of patent foramen ovale and usefulness of percutaneous closure device in carcinoid heart disease. Am J Cardiol 2008; 101: 1035-1038.
120. Arnold R, Chen YJ, Costa F, et al: ENETS consensus guidelines for the standards of care in neuroendocrine tumours: Follow-up and documentation. Neuroendocrinology 2009; 90: 227-233.
121. Moertel CG: Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5: 1502-1522.
122. In't Hof KH, van der Wal HC, Kazemier G, et al: Carcinoid tumour of the appendix: An analysis of 1,485 consecutive emergency appendectomies. J Gastrointest Surg 2008; 12: 1436-1438.
123. Modlin IM, Lye KD, Kidd M: A five-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959. (Pubitemid 36173145)
124. Lepage C, Rachet B, Coleman MP: Survival from malignant digestive endocrine tumors in England and Wales: A populationbased study. Gastroenterology 2007; 132: 899-904. (Pubitemid 46440869)
125. Moertel CG, Dockerty MB, Judd ES: Carcinoid tumors of the vermiform appendix. Cancer 1968; 21: 270-278.
126. Goede AC, Caplin ME, Winslet MC: Carcinoid tumour of the appendix. Br J Surg 2003; 90: 1317-1322. (Pubitemid 37421663)
127. Iwuagwu OC, Jameel JK, Drew PJ, et al: Primary carcinoma of the appendix -Hull series. Dig Surg 2005; 22: 163-167. (Pubitemid 41330836)
128. Fornaio R, Frascio M, Sticchi C, et al: Appendectomy or right hemicolectomy in the treatment of appendiceal carcinoid tumors? Tumori 2007; 93: 587-590. (Pubitemid 351158070)
129. Groth SS, Virnig BA, Al-Refaie WB, et al: Appendiceal carcinoid tumors: Predictors of lymph node metastasis and the impact of right hemicolectomy on survival. J Surg Oncol 2011; 103: 39-45.
130. McGory ML, Maggard MA, Kang H, et al: Malignancies of the appendix: Beyond case series reports. Dis Colon Rectum 2005; 48: 2264-2271. (Pubitemid 43074447)
131. Landry CS, Woodall C, Scoggins, et al: Analysis of 900 appendiceal carcinoid tumors for a proposed predictive staging system. Arch Surg 2008; 143: 664-670. (Pubitemid 352040236)
132. McCusker ME, Cote TR, Clegg LX, et al: Primary malignant neoplasms of the appendix: A population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer 2002; 94: 3307-3312. (Pubitemid 34670516)
133. Lepage C, Ciccolallo L, De Angelis R, et al: European disparities in malignant digestive endocrine tumours survival. Int J Cancer 2010; 126: 2928-2934.
134. Moertel CG, Weiland LH, Nagorney DM, et al: Carcinoid tumor of the appendix: Treatment and prognosis. N Engl J Med 1987; 317: 1699-1701. (Pubitemid 18024410)
135. Stinner B, Rothmund M: Neuroendocrine tumours (carcinoids) of the appendix. Best Pract Res Clin Gastroenterol 2005; 19: 729-738. (Pubitemid 41614120)
136. Deans GT, Spence RA: Neoplastic lesions of the appendix. Br J Surg 1995; 82: 299-306.
137. O'Donnell ME, Carson J, Garstin WIH, et al: Surgical treatment of malignant carcinoid tumours of the appendix. Int J Clin Pract 2007; 61: 431-437.
138. Pickhardt PJ, Levy AD, Rohrmann CA, et al: Primary neoplasms of the appendix: Radiologic spectrum of disease with pathologic correlation. Radiographics 2003; 23: 645-662. (Pubitemid 37431245)
139. Prommegger R, Ensinger C, Adlassnig C, et al: Catestatin -a novel neuropeptide in carcinoid tumors of the appendix. Anticancer Res 2004; 24: 311-316. (Pubitemid 38279724)
140. Modlin IM, Kidd M, Latich I, et al: Genetic differentiation of appendiceal tumor malignancy: A guide for the perplexed. Ann Surg 2006; 244: 52-60. (Pubitemid 44297448)
141. Prommegger R, Obrist P, Ensinger C, et al: Retrospective evaluation of carcinoid tumors of the appendix in children. World J Surg 2002; 26: 1489-1492. (Pubitemid 36920211)
142. Parkes SE, Muir KR, Sheyyab M, et al: Carcinoid tumours of the appendix in children 1957-1986: Incidence, treatment and outcome. Br J Surg 1993; 80: 502-504. (Pubitemid 23116097)
143. Bamboat ZM, Berger DL: Is right hemicolectomy for 2.0-cm appendiceal carcinoids justified? Arch Surg 2006; 141: 349-352.
144. Alexandraki KI, Griniatsos J, Bramis KI, et al: Clinical value of right hemicolectomy for appendiceal carcinoids using pathologic criteria. J Endocrinol Invest 2011; 34: 255-259.
145. Dunn JP: Carcinoid tumours of the appendix: 21 cases, with a review of the literature. NZ Med J 1982; 95: 73-76. (Pubitemid 12156208)
146. Prommegger R, Obrist P, Ensinger C, et al: Secretoneurin in carcinoids of the appendiximmunohistochemical comparison with chromogranins A, B and secretogranin II. Anticancer Res 1998; 18: 3999-4002. (Pubitemid 29043604)
147. Rossi G, Valli R, Bertolini F, et al: Does mesoappendix infiltration predict a worse prognosis in incidental neuroendocrine tumors of the appendix? A clinicopathologic and immunohistochemical study of 15 cases. Am J Clin Pathol 2003; 120: 706-711. (Pubitemid 37339677)
148. Tang LH, Shia J, Soslow RA, et al: Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol 2008; 32: 1429-1443.
149. Hemminki K, Li X: Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer 2001; 92: 2204-2210.
150. Jiang Y Long H, Wang W, et al: Clinicopathological features and immunoexpression profiles of goblet cell carcinoid and typical carcinoid of the appendix. Pathol Oncol Res 2011; 17: 127-132.
151. Toumpanakis C, Standish RA, Baishnab E, et al: Goblet cell carcinoid tumors (adenocarcinoid) of the appendix. Dis Colon Rectum 2006; 50: 315-322.
152. Pham TH, Wolff B, Abraham SC, et al: Surgical and chemotherapy treatment outcomes of goblet cell carcinoid: A tertiary cancer center experience. Ann Surg Oncol 2006; 13: 370-376. (Pubitemid 43255921)
153. Bucher P, Gervaz P, Ris F, et al: Surgical treatment of appendiceal adenocarcinoid (goblet cell carcinoid). World J Surg 2005; 29: 1436-1439. (Pubitemid 41712678)
154. Mandai M, Konishi I, Tsuruta Y, et al: Krukenberg tumor from an occult appendiceal adenocarcinoid: A case report and review of the literature. Eur J Obstet Gynecol Reprod Biol 2001; 97: 90-95. (Pubitemid 32619124)
155. Hristov AC, Young RH, Vang R, et al: Ovarian metastases of appendiceal tumors with goblet cell carcinoid-like and signet ring cell patterns: A report of 30 cases. Am J Surg Pathol 2007; 31: 1502-1511. (Pubitemid 47482462)
156. Pahlavan PS, Kanthan R: Goblet cell carcinoid of the appendix. World J Surg Oncol 2005; 3: 36.
157. Maggard MA, O'Connell JB, Ko CY: Updated population-based review of carcinoid tumors. Ann Surg 2004; 240: 117-122. (Pubitemid 38808243)
158. Dromain C, de Baere T, Lumbroso J, et al: Detection of liver metastases from endocrine tumors: A prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005; 23: 70-78. (Pubitemid 41702624)
159. Grimelius L: Methods in neuroendocrine histopathology -a methodological overview. Ups J Med Sci 2008; 113: 243-260.
160. Wang HL, Dhall D: Goblet or signet ring cells -that is the question. Adv Anat Pathol 2009; 16: 247-254.
161. Van Eeden S, Offerhaus GJA, Hart AAM, et al: Goblet cell carcinoid of the appendix: A specific type of carcinoma. Histopathology 2007; 51: 763-773. (Pubitemid 350179418)
162. Alsaad K, Serra S, Perren A, et al: CK19 and CD99 immunoexpression profile in goblet cell (mucin-producing neuroendocrine tumors) and classical carcinoids of the vermiform appendix. Int J Surg Pathol 2007; 15: 252-257. (Pubitemid 46976538)
163. La Rosa S, Finzi G, Puppa G, et al: Lipid-rich variant of appendiceal well-differentiated endocrine tumor (carcinoid). Am J Clin Pathol 2010; 133: 809-814.
164. Chetty R: Goblet cell carcinoid tumours of the appendix: A unique neuroendocrine tumour. Histopathology 2008; 52: 770-771. (Pubitemid 351600061)
165. Kanthan R, Saxena A, Kanthan SC: Goblet cell carcinoids of the appendix: Immunophenotype and ultrastructural study. Arch Pathol Lab Med 2001; 125: 386-390. (Pubitemid 32207177)
166. Alsaad KO, Serra S, Schmitt A, et al: Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix. Endocr Pathol 2007; 18; 16-22. (Pubitemid 47345616)
167. Chetty R, Klimstra DS, Henson DE, et al: Combined classical carcinoid and goblet cell carcinoid tumor: A new morphologic variant of carcinoid tumor of the appendix. Am J Surg Pathol 2010; 34: 1163-1167.
168. Butler JA, Houshiar A, Lin F, et al: Goblet cell carcinoid of the appendix. Am J Surg 1994; 168: 685-687. (Pubitemid 24378541)
169. Garin L, Corbinais S, Boucher E, et al: Adenocarcinoid of the appendix vermiformis complete and persistent remission after chemotherapy (folfox) of a metastatic case. Dig Dis Sci 2002; 47: 2760-2762. (Pubitemid 35471619)
170. Mahteme H, Sugarbaker PH: Treatment of peritoneal carcinomatosis from adenocarcinoid of appendiceal origin. Br J Surg 2004; 91: 1168-1173. (Pubitemid 39179461)
171. Ezziddin S, Opitz M, Attassi M, et al: Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2011; 38: 459-466.
172. Arnold R, Rinke A, Klose KJ, Muller HH, Wied M, Zamzow K, et al: Octreotide versus octreotide plus interferon in endocrine gastroenteropancreatic tumors: A randomized trial. Clin Gastroenterol Hepatol 2005; 3: 761-771. (Pubitemid 41116728)
173. Faiss S, Pape UF, Bohmig M, et al: International Lanreotide and Interferon Alfa Study Group: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors. J Clin Oncol 2003; 21: 2689-2696. (Pubitemid 46606312)
174. Kwekkeboom DJ, de Herder WW, van Eijck CH, et al: Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010; 40: 78-88.
175. Kwekkeboom DJ, de Herder WW, Kam BL, et al: Treatment with the radiolabeled somatostatin analog [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.
176. Pavel M, Hainsworth JD, Baudin E, et al: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet 2011; 378:2005-2012.
177. Kwekkeboom D J, Krenning EP, Lebtahi R, et al: ENETS consensus guidelines for the standards of care in neuroendocrine tumours: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009; 90: 220-226.